Genetic medicines expert Emily Walsh Martin shares learnings from Day 2 of #ASGCT2024
Emily Walsh Martin covers regulatory comments from FDA's Peter Marks, scientific updates on prime and base editing, and more.
top of page
Follow BiotechTV
Also look for unique social pages for BiotechTV U.
.png){kind=logo}
Popular
#1. Ultragenyx's Emil Kakkis on Angelman syndrome data, rare disease treatment modalities, and more
​
#2. The CEO of Madrigal on the launch of Rezdiffra for NASH liver disease
​
#3. Sutro Biopharma's CEO on ADCs, non-cell protein synthesis, and more
​
#4. Verve Therapeutics' CEO on today's gene editing clinical trial pause
#5. Daphne Zohar on becoming the CEO of Seaport Therapeutics and a $100M series A
bottom of page